Dual Antiplatelet Therapy With Cilostazol Cuts Recurrent Stroke Dual Antiplatelet Therapy With Cilostazol Cuts Recurrent Stroke

New results show cilostazol plus aspirin or clopidogrel reduced recurrent stroke rate by half over aspirin or clopidogrel alone in high-risk stroke patients without increased bleeding.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

Authors: Cervantes CE, Merino JL, Barrios V Abstract INTRODUCTION: Edoxaban is the last direct oral anticoagulant marketed for the prevention of stroke among patients with nonvalvular atrial fibrillation (AF). Areas covered: ENGAGE AF-TIMI 48 was the pivotal clinical trial that led to the approval of edoxaban 60 mg once daily. After the publication of this study, a great number of substudies and post hoc analyses have been published, together with some observational studies. The aim of this review was to update the current evidence about the use of edoxaban in AF patients. Expert commentary: In the ENGAGE AF-TIMI 4...
Source: Expert Review of Cardiovascular Therapy - Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research
CONCLUSIONS: This study adds an attempt for treatment ranking of both efficacy and safety outcomes. Future trials comparing directly NOACs are needed in order to provide conclusive proofs for these results and not only circumstantial evidence offered by a network meta-analysis. PMID: 30896311 [PubMed - as supplied by publisher]
Source: Scandinavian Cardiovascular Journal - Category: Cardiology Tags: Scand Cardiovasc J Source Type: research
ConclusionsCDT seems to have similar outcomes with ST in the management of acute PE, although larger, more homogenous data are needed. In our experience, ST should be viewed as a complementary alternative for patients with contraindication for thrombolytics or severely compromised hemodynamic profile and can yield good outcomes in an otherwise highly morbid population.
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - Category: Surgery Source Type: research
gro G Abstract Background: Combination of dual antiplatelet (DAPT) and oral anticoagulation therapy is required to decrease cardioembolic stroke and stent thrombosis risk in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). We compared the safety and efficacy of dabigatran etexilate with vitamin K antagonist (VKA), in combination with DAPT (aspirin plus clopidogrel) treatment in AF patients who underwent percutaneous coronary intervention (PCI) with stenting for ACS. Methods: Consecutive nonvalvular AF patients who received twice-daily dabigatran 110 mg (n = 389) or VKA (n = 510) and D...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
ConclusionSSRI use was associated with a significant decrease in MACE rates compared with patients receiving mirtazapine. Bleeding risk was not affected by either antidepressant treatment. SSRIs may have cardioprotective benefits compared with mirtazapine.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
ConclusionIn patients suffering from severe CS due to AMI, the use of Impella is not associated with improved short-time survival but with higher complications rates compared to IABP and medical treatment. Better patient selection avoiding Impella implantation in futile situations or in possible lower risk CS might be necessary to elucidate possible advantages of Impella in future studies.
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
CONCLUSIONS: The experimental treatment strategy of one-month DAPT followed by 23 months of ticagrelor alone did not result in a significant reduction in the rates of site-reported POCE or NACE, when compared to the reference treatment. PMID: 30888959 [PubMed - as supplied by publisher]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
WEDNESDAY, March 20, 2019 -- For patients with atrial fibrillation (AF), catheter ablation does not significantly reduce the risk for death, disabling stroke, serious bleeding, or cardiac arrest, but it does improve quality of life versus medical...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ConclusionsData from this meta-analysis suggest that, vs warfarin, the stroke prevention effectiveness and bleeding risk of direct oral anticoagulants may differ in real-life patients with atrial fibrillation.ResumenIntroducción y objetivosDeterminar la efectividad de los anticoagulantes orales directos frente a los antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clínica.MétodosSe realizó una revisión sistemática acorde con los estándares metodológicos de Cochrane. Los resultados de la revisión se publicaro...
Source: Revista Espanola de Cardiologia - Category: Cardiology Source Type: research
Publication date: Available online 19 March 2019Source: Canadian Journal of CardiologyAuthor(s): Federico Fortuni, Gabriele Crimi, Filippo Angelini, Sergio Leonardi, Fabrizio D’Ascenzo, Marco Ferlini, Marco Rolando, Arturo Raisaro, Luigi Oltrona Visconti, Maurizio Ferrario, Massimiliano Gnecchi, Gaetano M. De FerrariAbstractBackgroundThe optimal strategy and timing of revascularization in hemodynamically stable patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease is unknown. We performed a systematic review and meta-analysis to explore the comparative efficacy and safety of early c...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
More News: Aspirin | Bleeding | Brain | Cilostazol | Clopidogrel | Health | Neurology | Neurosurgery | Plavix | Stroke